Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization

Cornea

Volumn 30, Issue 1, 2011, Pages 30-33

  You, In Cheon ^a,b   Im, Seong Kyu ^a   Lee, Seung Hyun ^a   Yoon, Kyung Chul ^a  

^a Chonnam National University Medical School   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

Author keywords

corneal neovascularization; photodynamic therapy; subconjunctival bevacizumab

Indexed keywords

BEVACIZUMAB; VERTEPORFIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORNEA NEOVASCULARIZATION; DRUG EFFICACY; EYE PHOTOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SLIT LAMP; THROMBOSIS; TREATMENT INDICATION; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; CONJUNCTIVA; CORNEAL NEOVASCULARIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PILOT PROJECTS; PORPHYRINS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; YOUNG ADULT;

EID: 78650959241     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181dc81a0     Document Type: Article

References (28)

1. Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249.
2. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45: 2666-2673.
3. Phillips K, Arffa R, Cintron C, et al. Effect of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization. Arch Ophthalmol. 1983;101:640-643.
4. Ambati BK, JoussenAM, Ambati J, et al. Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol. 2002;120:1063-1068.
5. Cursiefen C, Masli S, Ng TF, et al. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci. 2004; 45:1117-1124.
6. Corrent G, Roussel TJ, Tseng SCG, et al. Promation of graft survival by photothrombotic occlusion of corneal neovascularization. Arch Ophthalmol. 1989;107:1501-1506.
7. Pillai CT, Dua HS, Hossain P. Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci. 2000;41:2148-2153.
8. Qian CX, Bahar I, Levinger E, et al. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008;27:1090-1092.
9. Yoon KC, You IC, Kang IS, et al. Photodynamic therapy with verteporfin for corneal neovascularization. Am J Ophthalmol. 2007;144:390-395.
10. Brooks BJ, Ambati BK, Marcus DM, et al. Photodynamic therapy for corneal neovascularization and lipid degeneration. Br J Ophthalmol. 2004;88:840.
11. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol. 1999;117:1329-1345.
12. Yoon KC, Ahn KY, Lee SE, et al. Experimental inhibition of corneal neovascularization by photodynamic therapy with verteporfin. Curr Eye Res. 2006;31:215-224.
13. AveryRL, PieramiciDJ,RabenaMD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-relatedmacular degeneration.Ophthalmology. 2006;113: 363-372.
14. Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol. 2007;91:804-807.
15. DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol. 2007;125:834-836.
16. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007;245:1577-1579.
17. You IC, Kang IS, Lee SH, et al. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol. 2009;87:653-658.
18. Doctor PP, Bhat PV, Foster CS. Subconjunctival bevacizumab for corneal neovascularization. Cornea. 2008;27:992-995.
19. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008;27:142-147.
20. Tatar O, Adam A, Shinoda K, et al. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol. 2006;142:95-104.
21. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005;25:111-118.
22. Awadein A. Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg. 2007;33:1991-1993.
23. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008;115:e33-e38.
24. Tatar O, Adam A, Shinoda K, et al. Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to age-related macular degeneration. Retina. 2007;27:713-723. (Pubitemid 47053860)
25. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2007;114:1179-1185.
26. Smith BT, Dhalla MS, Shah GK, et al. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina. 2008;28:675-681.
27. Lai TY, Chan WM, Liu DT, et al. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008;92:661-666.
28. Saito M, Shiragami C, Shiraga F, et al. Combined intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol. 2008;146:935-941.